NEUROONE MEDICAL TECHNOLOGIES Business Summary

NeuroOne Medical Technologies (NMTC) is a medical technology company focused on the commercialization of thin-film electrode systems for the surgical diagnosis and treatment of neurological disorders, including epilepsy, Parkinson’s disease, and chronic pain. The company’s revenue model is driven by product sales of its FDA-cleared Evo® Cortical and sEEG electrodes and the OneRF® Ablation System, supplemented by licensing fees and milestone payments from an exclusive global distribution partnership with Zimmer Biomet. Its business segments are divided into diagnostic recording, therapeutic ablation, and a development pipeline targeting drug delivery and spinal cord stimulation. Within a competitive landscape featuring ClearPoint Neuro, Nyxoah, and Apyx Medical, NeuroOne distinguishes itself by providing the market's first integrated platform capable of both high-definition EEG monitoring and radiofrequency ablation through a single, minimally invasive implant. The leadership team is anchored by President and CEO Dave Rosa, who previously held senior roles at St. Jude Medical and Nuwellis, and CTO Steve Mertens, an engineering veteran with a background at Boston Scientific and Medtronic. The company was founded by Mark Christianson, who continues to serve as Director of Business Development, alongside a management suite including CFO Ronald McClurg and COO Christopher Volker. Governance is overseen by Chairman Paul Buckman, CEO of Rhythmlink and former LivaNova executive, and Director Jason Mills, EVP of Strategy at Penumbra. NeuroOne is supported by notable institutional investors such as Merchant Adventure Fund, Sio Capital Management, and Vanguard, with a capital position secured through fiscal 2026 to support its expansion into trigeminal nerve ablation and international markets.